Plasma-derived VWF-FVIII (2.4:1, Humate-P) was from CSL Behring (King of Prussia, USA), and (1:1, Wilate) was from Octapharma, Lachen, Switzerland. Human recombinant FVIII (rFVIII) products included Advate (Baxter, Deerfield, USA), Kogenate-FS and Kovaltry (Bayer, Leverkusen, Germany), Xyntha (Pfizer, New York, USA), and Nuwiq (Octapharma). Plasma-derived FVIII (pdFVIII) (Haemocetin) (Biotest, Dreieich, Germay) had been purified to contain 1% VWF. All experiments unless otherwise specified were performed with Advate (rFVIII) or Humate P (pdVWF-FVIII).
Kovaltry
Manufactured by Bayer
Sourced in United States
Kovaltry is a coagulation factor VIII product used for the treatment and prevention of bleeding episodes in patients with hemophilia A. It serves as a replacement for the missing or deficient factor VIII protein in the blood, which is necessary for proper blood clotting.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using kovaltry
1
Comparative Study of FVIII and VWF-FVIII Products
2
Pharmacokinetic Comparison of BAY 81-8973 and rAHF-PFM
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
This was a phase I, single-dose, open-label, randomized, crossover study to compare the PK of BAY 81-8973 with rAHF-PFM (ClinicalTrials.gov identifier: NCT02483208). Patients (N = 18) were randomized according to a computer-generated randomization list to receive a single infusion of 50 IU/kg BAY 81-8973 (Kovaltry®; Bayer, Berkeley, CA, USA) or 50 IU/kg rAHF-PFM (Advate®; Baxalta, Westlake Village, CA, USA), followed by crossover to a single infusion of the other treatment, with washout periods of ≥3 days before each single dose. Both products were administered as 10-min intravenous infusions. Informed consent was provided by the patients, and the protocol was approved by the site’s independent Ethics Committee/Institutional Review Board.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!